Delfi Diagnostics

Delfi Diagnostics is a biotechnology company pioneering a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring. The company utilizes a proprietary 'fragmentomics' platform that analyzes cell-free DNA (cfDNA) fragmentation patterns across the whole genome using machine learning, offering a cost-effective and scalable approach to cancer screening. Delfi's technology is designed to detect cancer signals that conventional mutation-based approaches might miss, with applications ranging from single-cancer early detection to multi-cancer screening and treatment monitoring. The company operates as a B2B partner for health systems and biopharma companies, providing research services and developing laboratory-developed tests (LDTs) like FirstLook Lung.